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NPV: Negative predictive value 
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Abstract:  
Background & Aims: Fibrosis affects prognoses for patients with nonalcoholic fatty liver 
disease (NAFLD). Several non-invasive scoring systems have aimed to identify patients at 
risk for advanced fibrosis, but inconclusive results and variations in features of patients 
(diabetes, obesity and older age) reduce their diagnostic accuracy. We sought to develop a 
scoring system based on serum markers to identify patients with NAFLD at risk for advanced 
fibrosis. 
 
Methods: We collected data from 2452 patients with NAFLD at medical centers in Italy, 
France, Cuba, and China. We developed the Hepamet fibrosis scoring system using 
demographic, anthropometric, and laboratory test data, collected at time of liver biopsy, from 
a training cohort of patients from Spain (n=768) and validated the system using patients from 
Cuba (n=344), Italy (n=288), France (n=830), and China (n=232). Hepamet fibrosis score 
(HFS) were compared with those of previously developed fibrosis scoring systems (the 
NAFLD fibrosis score [NFS] and FIB-4). The diagnostic accuracy of the Hepamet fibrosis 
scoring system was assessed based on area under the receiver operating characteristic 
(AUROC) curve, sensitivity, specificity, diagnostic odds ratio, and positive and negative 
predictive values and likelihood ratios. 
 
Results: Variables used to determine HFS were patient sex, age, homeostatic model 
assessment score, presence of diabetes, levels of aspartate aminotransferase, and albumin, and 
platelet counts; these were independently associated with advanced fibrosis. HFS 
discriminated between patients with and without advanced fibrosis with an AUROC curve 
value of 0.85 whereas NFS or FIB-4 did so with AUROC values of 0.80 (P=.0001). In the 
validation set, cut-off HFS of 0.12 and 0.47 identified patients with and without advanced 
fibrosis with 97.2% specificity, 74% sensitivity, a 92% negative predictive value, a 76.3% 
positive predictive value, a 13.22 positive likelihood ratio, and a 0.31 negative likelihood 
ratio. HFS were not affected by patient age, body mass index, hypertransaminasemia, or 
diabetes. The Hepamet fibrosis scoring system had the greatest net benefit in identifying 
patients who should undergo liver biopsy analysis and led to significant improvements in 
reclassification, reducing the number of patients with undetermined results to 20% from 30% 
for the FIB-4 and NFS systems (P<.05). 
 
Conclusions: Using clinical and laboratory data from patients with NAFLD, we developed 
and validated the Hepamet fibrosis scoring system, which identified patients with advanced 
fibrosis with greater accuracy than the FIB-4 and NFS systems. the Hepamet system provides 
a greater net benefit for the decision-making process to identify patients who should undergo 
liver biopsy analysis. 
 
KEY WORDS: HOMA, steatosis, prognostic factor, diagnostic tool, cirrhosis 
 
Need to Know 
 
Background: Non-invasive scoring systems are needed to detect and monitor liver fibrosis in 
patients with NAFLD because the reliability of liver biopsy analysis is limited. Previously 
developed systems (the NFS and FIB-4 systems) have limited accuracy in identifying patients 
with advanced fibrosis. Their scores are affected by patient body mass index and age, 
requiring adjusted cut-off values to increase their specificity.  
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Findings: We developed a scoring system, called the Hepamet fibrosis scoring system, based 
on clinical and laboratory test results. This system identified patients with NAFLD who had 
advanced fibrosis with a high level of specificity, and did not require adjustment of cut-off 
scores to increase its accuracy or the number of patients correctly classified. Hepamet fibrosis 
scores identified patients with advanced fibrosis with higher levels of accuracy than the NFS 
and FIB-4 systems in an independent validation cohort.  
 
Implications for patient care: The Hepamet fibrosis scoring system can be used in primary 
care to identify patients with fatty liver disease at highest risk for advanced fibrosis and 
reduce unnecessary referrals and in specialized units to increase detection of advanced 
fibrosis. 
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INTRODUCTION 
The burden of non-alcoholic fatty liver disease (NAFLD) has been dramatically growing in 
parallel with obesity, diabetes, and metabolic syndrome outbreaks1. NAFLD has become the 
most common cause of chronic liver disease, representing a risk factor for cirrhosis, 
hepatocellular carcinoma, and liver transplantation2, as well as for extra-hepatic 
manifestations such as cardiovascular34 and kidney disease5, and extrahepatic malignancies6. 
Fibrosis has been identified as the major determinant of the long-term prognosis of NAFLD 
patients7. In the current scenario, the correct identification of patients at risk of progression is 
a critical step in the management of NAFLD8. No symptoms and normal transaminase levels 
are common features of NAFLD. Thus, we need to develop tools able to detect this silent 
entity. Liver biopsy has been considered the gold standard for the diagnosis of NAFLD, 
although it is sometimes imperfect due to sample-to-sample variability and interpretation, and 
some additional concerns such as the cost and potential complications. Several algorithms 
based on serological biomarkers have been developed to identify patients at risk of advanced 
fibrosis. Both NAFLD fibrosis score (NFS)9 and FIB-4 index10 are the serological non-
invasive methods most widely used to exclude the presence of advanced fibrosis. However, 
they have shown some limits such as the influence of baseline variables included in the 
formula to calculate the score (i.e., age11 in FIB-4 and obesity in NFS12). Moreover, non-
interpretable results (so-called grey zone) could reach up to 30% of patients13 in these tests. 
The identification of NAFLD patients at risk of liver fibrosis progression is a critical unmet 
need representing a timely challenge for clinicians. In this study, we developed a serum-based 
non-invasive score to improve the prediction of advanced fibrosis and further diagnostic 
decision-making process in patients with NAFLD. 
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METHODS 
Selection of Patients 
An international multicenter cross-sectional study was designed including 2,452 consecutive 
biopsy-proven NAFLD patients. The research was initially conducted with patients from the 
Spanish HEPAmet Registry. This registry is governed by the Spanish Association for the 
Study of the Liver (AEEH) and the Network of Biomedical Research Centre for the Study of 
the Liver and Digestive Diseases (CIBERehd). Monitoring is a fundamental element of the 
database, ensuring the accuracy of data and minimization of bias. The study was later 
externally validated in biopsy-proven NAFLD patients from geographically separate tertiary 
international medical centers from Italy, France (two independent hospitals), Cuba, and 
China. 
Patients underwent a liver biopsy according to the routine decisions in the clinical practice. 
The inclusion criterium was biopsy-proven NAFLD, irrespective of the existence of NASH or 
fibrosis stage. Exclusion criteria were significant alcohol intake (>30 g daily for men and 
>20g daily for women) and evidence of concomitant liver disease (i.e., viral or autoimmune 
hepatitis, HIV, drug-induced fatty liver, hemochromatosis or Wilson’s disease). The study 
was performed in agreement with the Declaration of Helsinki and with local and national laws 
and approved by the Ethics and Clinical Research Committee of every center. All patients 
were informed of the nature of the study and gave their written consent to participate. 
Clinical assessment 
Demographic characteristics, anthropometric measures, and laboratory tests (ALT, AST, 
GGT, triglycerides, cholesterol, HDL-c, LDL-c, fasting glucose, HbA1c, insulin, creatinine, 
albumin) were recorded at the same time of liver biopsy. A fasting blood sample was taken 
for routine biochemical analyses. HOMA was calculated based on insulin and glucose (fasting 
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insulin x fasting glucose / 405). Furthermore, NAFLD Fibrosis Score9 and FIB-410,14 were 
computed. 
Histological assessment 
The diagnosis of NAFLD was based on histological criteria. All liver biopsies were assessed 
by experienced hepato-pathologists, who were blinded regarding patient’s evaluation and 
clinical data. Samples of <15 mm length or <10 portal tracts were considered not suitable for 
diagnosis and fibrosis staging and were excluded. To define steatohepatitis, we used SAF 
scoring system15 combining steatosis, inflammatory activity, and fibrosis. Several histological 
aspects were measured. First, steatosis was rated as 1 (5%-33%), 2 (33%-66%) and 3 (>66%). 
Second, activity grade is the addition of hepatocyte ballooning (0–2) and lobular 
inflammation (0–2). Lastly, liver fibrosis was taken into account the fibrosis shown in zone 3 
perisinusoidal: F0 (none portal fibrosis), F1 (some-most portal fibrosis), F2 (few bridging 
fibrosis), F3 (much-bridging fibrosis), F4 (cirrhosis). We defined advanced fibrosis (F0-2 vs. 
F3-F4) for statistical purposes. 
Objectives 
We aimed to develop a serological non-invasive score (based on standard variables) to predict 
fibrosis in patients with NAFLD, for the following purposes: a) to improve the advanced 
fibrosis screening compared to the most used non-invasive methods (NFS and FIB-4); b) to 
assess the effectiveness of the score to predict advanced fibrosis in presence of baseline 
conditions that could bias the results (age, BMI, diabetes, and hypertransaminasemia); c) to 
assess the health outcomes of the implementation of the score on the diagnostic decision-
making process. 
Statistical analyses 
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Variables used for the Hepamet Fibrosis Score were measured at enrolment. To develop and 
validate our model, we drew two independent cohorts of 758 subjects for model development 
(Spanish cohort) and 1,694 individuals for model validation [French No.1 (n=444), French 
No.2 (n=386), Italian (n=288), Cuban (n=344), and Chinese (n=232) cohorts]. Data were 
reported as the mean ± standard deviation for normal and median (interquartile range) for 
non-normal continuous variables, while frequency was used for discrete variables. In the 
univariable comparisons, we used the Student t-test and ANOVA with Bonferroni 
adjustments for continuous samples and chi-square test or Fisher’s exact test for qualitative 
ones. Non-parametric alternatives (Mann–Whitney U and Kruskal-Wallis tests) were used for 
non-normal distributions. Independent variables with significance p≤0.10 were introduced in 
a first multivariable analysis (backward Wald logistic regression analysis) to identify factors 
independently related to advanced fibrosis. To improve the prediction, a second multivariable 
analysis was performed after the transformation of the continuous variables into qualitative 
and ordinal ones according to the thresholds corresponding to a fourth and a two-times higher 
prevalence for advanced fibrosis (Supplementary Figure 1). Odds ratios (OR) and their 95% 
confidence intervals were estimated. Values were considered to be statistically significant 
when p<0.05. Akaike’s information criterion, which is an estimator of the relative quality of 
statistical models for a given set of data, was additionally computed to select the most robust 
predictors. 
The calibration of the Hepamet Fibrosis Score was assessed using a calibration belt16. It 
creates a confidence band for the calibration curve based on a function that relates expected to 
observed probabilities of advanced fibrosis across classes of risk. The calibration belt 
identifies significant deviations from the ideal calibration, as well as the direction of the 
variation. The area under the ROC curve (AUROC) was computed to corroborate the results 
observed in the derivation and validation sets, determine the diagnostic accuracy of the 
predictive models and select different thresholds for predicting advanced fibrosis. Youden 
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Index (sensitivity + specificity – 1)17 was calculated to identify the optimal lower cut-off, and 
the higher cut-off was determined to show 97% of specificity. The sensitivity, specificity, 
positive predictive value (PPV), negative predictive value (NPV), percent correctly classified, 
likelihood ratios and diagnostic odds ratio (OR) were computed for the selected cutoffs, as 
well as the post-tests probabilities. We presented a decision curve analysis to evaluate (net 
benefit) whether the application of the prediction model does more good (identification of 
advanced fibrosis) than harm (unnecessary biopsy). The selected probability thresholds 
represented the level of diagnostic certainty above which the patient would choose to be 
biopsied. The highest curve at any given threshold probability is the optimal decision-making 
strategy to maximize the net benefit18. Also, we calculated the net reclassification index (NRI) 
and the integrated discrimination index (IDI) to address the risk refinement and the 
incremental prognostic impact of the Hepamet Fibrosis Score19. 
The method used for missing data was complete-case analysis since statistical packages 
excluded individuals with any missing value. STATA (12.0, STATA Corporation, College 
Station, TX, USA) statistical package was used in all analyses and GraphPad Prism (version 
6.0; GraphPad Software, Inc., La Jolla, CA) for graphics. 
 
RESULTS 
Patients’ characteristics 
Table 1 shows the baseline features of the estimation and validation cohorts (the individual 
sets can be seen in Table S1). Out of the overall cohort, 54.5% of patients were males with a 
mean age of 51.9±13.1 years old. The overall prevalence of significant and advanced fibrosis 
and cirrhosis was 37.7% (925/2452), 20.6% (506/2452) and 5.7% (140/2452), respectively. 
Briefly, patients included in the estimation cohort were older and showed lower levels of 
transaminases, HOMA, and triglycerides than the validation cohort. In addition, the training 
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set showed a higher prevalence of obesity and a lower rate of diabetes. Regarding liver 
damage, the percentage of significant and advanced fibrosis, as well as cirrhosis was lower in 
the estimation (22%, 12.1%, and 2.9%, respectively) than the validation population (44.7%, 
24.4%, and 7%, respectively). 
Development of Hepamet Fibrosis Score 
The first step to develop our model was to perform the univariable analysis in the estimation 
cohort. We found the following variables associated with advanced fibrosis: age (p=0.0001), 
female sex (p=0.001), diabetes (p=0.0001), ALT (p=0.002), AST (p=0.0001), albumin 
(p=0.0001), HOMA (p=0.0001), total cholesterol (p=0.017), and platelets (p=0.0001). The 
first multivariable analysis (including quantitative variables) showed age [OR 1.05 (95%CI 
1.03-1.08); p=0.0001], female sex [OR 2.08 (95%CI 1.18-3.66); p=0.011], diabetes [OR 1.66 
(95%CI 0.92-3.00); p=0.093], HOMA [OR 1.16 (95%CI 1.10-1.23); p=0.0001], AST [OR 
1.02 (95%CI 1.01-1.03); p=0.0001], albumin [OR 2.54 (95%CI 1.30-4.98); p=0.006], and 
platelets [OR 0.99 (95%CI 0.987-0.995); p=0.0001] independently associated with advanced 
fibrosis (Table S2). 
The second multivariable analysis, after transforming the quantitative into categorical 
variables, found the following variables associated with advanced fibrosis in the estimation 
cohort: female sex [OR 2.40 (95%CI 1.33-4.33); p=0.004], age 45-64 years old [OR 2.68 
(95%CI 1.06-6.77); p=0.037], age ≥65 years old [OR 5.58 (95%CI 2.09-14.92); p=0.001], 
HOMA ≥4 [OR 4.47 (95%CI 1.49-13.42); p=0.008], diabetes [OR 8.88 (95%CI 3.10-25.44); 
p=0.0001], AST 35-69 IU/L [OR 2.45 (95%CI 1.37-4.38); p=0.002], AST ≥70 IU/L [OR 8.38 
(95%CI 3.72-18.91); p=0.0001], albumin <4 g/dL [OR 2.45 (95%CI 1.14-5.29); p=0.022], 
platelets 155-220 x109/L [OR 2.42 (95%CI 1.35-4.34); p=0.003], and platelets <155 x109/L 
[OR 9.33 (95%CI 4.01-21.67); p=0.0001] (Table 2). The discrimination ability of the second 
multivariable analysis was higher than the first one (Figure S2). 
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Therefore, the individual risk score for advanced fibrosis was calculated using the following 
formula derived from the multivariable analysis:  
1 / (1 + e (5.390 - 0.986 x Age [45-64 years old] – 1.719 x Age [>65 years old] + 0.875 x Male sex– 0.896 x AST [35-69 IU/L] – 2.126 
x AST [>70 IU/L] – 0.027 x Albumin [4-4.49 g/dL] – 0.897 x Albumin [<4 g/dL] – 0.899 x HOMA [2-3.99 with no DM] – 1.497 x HOMA 
[>4 with no DM] – 2.184 x Diabetes Mellitus – 0.882 x platelets x 1.000/microL [155-219] – 2.233 x platelets x 1.000/microL [<155]). 
A freely online application to estimate the predicted advanced fibrosis rate is available at the 
following website: https://www.hepamet-fibrosis-score.eu/. 
Calibration and discrimination ability of Hepamet Fibrosis Score 
Figure S3 shows the observed and predicted probability of advanced fibrosis by Hepamet 
Fibrosis Score in the estimation and validation sets. Predicted and observed probabilities of 
advanced fibrosis were similar in the derivation (p=0.351) and validation cohorts (p=0.815). 
We show the discrimination ability of the different scores for the estimation and validation 
cohorts in Table 3a and cohort-by-cohort in Table S3. Hepamet Fibrosis Score was 
significantly superior to NFS and FIB-4 both in the estimation cohort and the validation set 
(Figure S4). Also, Hepamet Fibrosis Score revealed the smallest Akaike’s information 
criterion value (HFS: AIC 1837 vs. FIB-4: AIC 2023 vs. NFS: AIC 2052). 
Validation of Hepamet Fibrosis Score 
The Hepamet Fibrosis Score cut-offs were 0.12 and 0.47 for advanced fibrosis in the 
estimation cohort. The performance of the model was evaluated using the same cut-offs in the 
validation cohort, demonstrating comparable results for advanced fibrosis (Table 3b). 
Besides, we show the sensitivity-specificity plot for the estimation and validation cohorts in 
Figure S5. Table S4 provides the diagnostic performance of Hepamet Fibrosis Score, NFS, 
and FIB-4 for the diagnosis of advanced fibrosis in the overall cohort. The prevalence of 
advanced fibrosis was significantly decreased with the lower cut-off of HFS (8%) in 
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comparison with NFS (10.7%; p=0.012) and FIB-4 (10.3%, p=0.027). Regarding the higher 
cut-off, HFS showed a greater prevalence of advanced fibrosis (76.3%) than NFS (55.6%; 
p<0.0001) and similar than FIB-4 (74.1%; p=0.603). The modifying probability plot for 
positive and negative likelihood ratio, depending on the cut-off of HFS, is shown in Figure 
S6. According to the number of patients with non-interpretable results, the “grey zone” was 
lower when using Hepamet Fibrosis Score (21%) than FIB-4 (26%; p<0.05) and NFS (30.8%; 
p<0.05). 
Influence of baseline variables on the Hepamet Fibrosis Score 
Hepamet Fibrosis Score showed a significantly higher diagnostic OR for the lower cut-off 
(<0.12) than age-adjusted FIB-4 and NFS to rule out advanced fibrosis, irrespective of the 
presence or absence of diabetes (Figure 1a) and hypertransaminasemia (Figure 1b), as well 
as BMI (Figure 1c) and age groups (Figure 1d). On the other hand, the higher cut-off of HFS 
(>0.47) was superior to NFS >0.675 to rule in advanced fibrosis in all scenarios. Comparing 
with FIB-4 >2.67, HFS >0.47 showed the greater difference in the diagnostic OR for the 
groups with a priori low risk of liver damage (lack of diabetes, ALT<40, lean and younger 
patients), while it was slightly better in high-risk patients (Figures 2a, 2b, 2c, and 2d). 
Clinical usefulness of Hepamet Fibrosis Score: A decision curve analysis 
A decision curve analysis was added to analyze the clinical utility of Hepamet Fibrosis Score 
guiding to perform a liver biopsy compared with NFS and FIB-4. The decision curve analysis 
indicated that, from a threshold probability of >10%, we could obtain more net benefit guided 
by Hepamet Fibrosis Score than the reference strategies (NFS and FIB-4) and to biopsy all or 
no patients. Particularly, we could obtain a net benefit of 10.4%, 6%, 3.1% and 1.1% at 
threshold probabilities of 20%, 40%, 60% and 80% (Figure 3). Although the percentages 
could seem low, it must be interpreted in the context of the prevalence. The maximum 
possible value of the net benefit that can be achieved in this study corresponds to the 
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prevalence of advanced fibrosis (20.6%). For example, a net benefit of 10.4% achieved at 
20% threshold probability represents until 50% (0.104/0.206*100%) of the maximal benefit. 
Hepamet Fibrosis Score led to significant improvements in reclassification, compared to NFS 
[NRI 31.7% (95%CI 15.1–48.2)] and FIB-4 [NRI 25.3% (95%CI 16–33.7)]. These results 
indicate that Hepamet Fibrosis Score correctly reclassified subjects with and without 
advanced fibrosis. Also, Hepamet Fibrosis Score improved the IDI significantly in 
comparison with NFS [IDI 0.1170 (95%CI 0.1077–0.1263)] and FIB-4 [IDI 0.07 (95%CI 
0.0624–0.0776)] (Supplementary Table 5). 
 
DISCUSSION 
In the current study, including a large international cohort of biopsy-proven NAFLD patients, 
we demonstrated that Hepamet Fibrosis Score (HFS) (including age, sex, diabetes, HOMA, 
AST, albumin, and platelets) determine liver fibrosis staging better than NFS and FIB-4. This 
new score showed greater clinical utility to guide the decision to make diagnostic liver 
biopsies in patients with NAFLD, representing a user-friendly tool that emerges as an 
accurate non-invasive method beyond transaminases to screen and manage a silent disease.  
Several serum-based methods have been developed to detect individuals at risk of advanced 
fibrosis in NAFLD20. NFS and FIB-4 (initially designed for hepatitis C21) are the most used 
scores, showing AUROCs around 0.80 for advanced fibrosis22. Hepamet Fibrosis Score 
improved the diagnostic accuracy significantly for advanced fibrosis in comparison with 
them. Two major strengths must be highlighted in its development: the wide external 
international validation and the statistical approach. Firstly, Hepamet Fibrosis Score has been 
calculated with almost 2,500 patients from five countries (Spain, France, Italy, Cuba, and 
China), including various ethnicities (Caucasian, Latin, and Asian populations) and different 
rates of baseline features (diabetes, obesity, the prevalence of fibrosis). Given that HFS scored 
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similarly between these cohorts, the final results must be considered robust. Secondly, we 
selected a multivariable analysis to develop the score using categorical variables. This 
approach showed better diagnostic accuracy because of the effect of capping age, platelets, 
albumin, and AST levels. For example, older age was associated with advanced fibrosis in our 
study, but its impact caused more false than true positive cases over than 65 years old, 
similarly to other studies11. Also, HOMA was combined with diabetes in the same variable to 
improve reliability and because HOMA is not a useful marker for insulin resistance in 
diabetes (i.e., it is modified by insulin sensitizers or exogenous insulin). Thus, HOMA does 
not need to be calculated in diabetic patients. On the other hand, HFS <0.12 showed the 
lowest negative and HFS >0.47 the highest positive likelihood ratio for advanced fibrosis. 
Consequently, the post-test probabilities using Hepamet Fibrosis Score were significantly 
better than NFS and FIB-4. 
Current biochemical non-invasive methods show some major drawbacks. On the one hand, 
there are a high proportion of patients allocated to the “grey zone” in NFS and FIB-423. By 
contrast, patients assigned to undetermined results were significantly lower for Hepamet 
Fibrosis Score than FIB-4 and NFS. On the other hand, many baseline factors can influence 
the diagnostic performance of serum-based scores. First, both NFS and FIB-4 require age-
adjusted cut-offs to improve the diagnostic accuracy (particularly, specificity) for advanced 
fibrosis in patients older than 65 years old11. By contrast, Hepamet Fibrosis Score did not 
require to be adjusted for age. Second, it has been estimated that up to two-thirds of cirrhotic 
patients showed normal levels of transaminases, which represent the main alert of underlying 
liver disease in clinical practice24. HFS showed the highest diagnostic effectiveness of the 
three scores in the population without hypertransaminasemia, so it could be useful covering 
the gap of early identification of at-risk NAFLD patients. Third, non-invasive scores have 
moderate success in predicting fibrosis in obese patients12. HFS had the highest diagnostic OR 
to rule out advanced fibrosis across all the BMI groups, while the higher cut-off was 
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significantly superior in lean patients compared with FIB-4 and NFS. Notably, the percentage 
of false positives rose dramatically with the BMI for NFS. Fourth, diabetes influences the 
accuracy of the prediction of the non-invasive scores25. In our study, HFS showed the highest 
diagnostic effectiveness of the scores in patients without diabetes, while it was slightly better 
than FIB-4 for patients with this entity.  
Adding decision curve analysis to statistical approaches based on metrics could help for 
clinical decision making26. In our study, this statistical approach weighed the true and false 
positive results of Hepamet Fibrosis Score (detecting advanced fibrosis vs. unnecessary 
biopsy) and demonstrated a greater net benefit leading the decision of performing a liver 
biopsy, compared to NFS and FIB-4. No previous calculation of net benefit has been found in 
the literature of non-invasive methods in NAFLD. Also, the NRI suggested that Hepamet 
Fibrosis Score was able to improve the correct classification of patients. This point is relevant 
because EASL guidelines recommend the use of non-invasive scores to help in decision 
making27. The usefulness of Hepamet Fibrosis Score on detection of NAFLD-fibrosis in 
general population by primary care and other non-hepatologist physicians should be 
addressed in future studies, as well as its combination with transient elastography in order to 
maximize the accuracy of the prediction of liver fibrosis. 
In summary, in this large international study, Hepamet Fibrosis Score demonstrated to be 
more accurate to stage liver fibrosis in NAFLD, with better calibration and net benefit, than 
NFS and FIB-4. Future studies analyzing the impact of HFS on clinical outcomes in NAFLD 
and a potential combination of Hepamet Fibrosis Score with imaging biomarkers to improve 
the continuum of care of the patients with NAFLD are warranted. 
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TABLE LEGENDS 
Table 1. Baseline characteristics of the estimation and validation cohorts. 
Table 2. Variables associated with advanced fibrosis in the estimation cohort. *BMI, ALT and 
total cholesterol were included in the multivariable analysis, but they were not significant. 
Table 3. A) Discrimination ability of the Hepamet Fibrosis Score, compared with NAFLD 
Fibrosis Score and FIB-4, in both estimation and validation cohorts. B) Operating 
characteristics for the two selected cut-offs of the Hepamet Fibrosis Score, regarding 
advanced fibrosis in both estimation and validation cohorts. *Age-adjusted cut-off for subjects 
older than 65 years old were used for NFS and FIB-4. 
Supplementary Table 1. Baseline characteristics of the individual cohorts. 
Supplementary Table 2. Univariable and multivariable analyses (including quantitative 
variables) regarding advanced fibrosis in the estimation cohort. 
Supplementary Table 3. Discrimination ability of the Hepamet Fibrosis Score, compared with 
NAFLD Fibrosis Score and FIB-4, cohort by cohort. 
Supplementary Table 4. Operating characteristics for the two selected cut-offs of the Hepamet 
Fibrosis Score, compared with NAFLD Fibrosis Score and FIB-4, regarding advanced fibrosis 
in the overall cohort.  
Supplementary Table 5. Net reclassification index and integrated discrimination improvement 
between Hepamet Fibrosis Score and the other models. 
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FIGURE LEGENDS 
Figure 1. Unadjusted diagnostic OR for advanced fibrosis for the lower cut-offs for Hepamet 
Fibrosis Score, NAFLD Fibrosis Score, and FIB-4, depending on: A) BMI; B) Age; C) 
Hypertransaminasemia; D) Diabetes mellitus. *Age-adjusted cut-off for subjects older than 65 
years old were used for NFS and FIB-4. 
Figure 2. Unadjusted diagnostic OR for advanced fibrosis for the higher cut-offs for Hepamet 
Fibrosis Score, NAFLD Fibrosis Score, and FIB-4, depending on: A) BMI; B) Age; C) 
Hypertransaminasemia; D) Diabetes mellitus. 
Figure 3. Decision curve analysis showing the highest net benefit of the strategy based on 
Hepamet Fibrosis Score. 
Supplementary Figure 1. Transformation of the continuous into qualitative variables. 
Supplementary Figure 2. Accuracy of the Hepamet Fibrosis Score, comparing the first and 
second multivariable analyses, in predicting advanced fibrosis in the estimation cohort. 
Supplementary Figure 3. Calibration belt for the Hepamet Fibrosis Score. A) Estimation 
cohort. B) Validation cohort. 
Supplementary Figure 4. Accuracy of the Hepamet Fibrosis Score, compared with NAFLD 
Fibrosis Score and FIB-4, in predicting advanced fibrosis in the estimation cohort.  
Supplementary Figure 5. Plot of sensitivity versus specificity for Hepamet Fibrosis Score. A) 
Estimation cohort. B) Validation cohort. 
Supplementary Figure 6. Plot showing post-test probability depending on the prevalence, and 
positive and negative likelihood ratios. A) HFS cut-off 0.12. B) HFS cut-off 0.47. 
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Characteristic Estimation Cohort 
(n=758) 
Validation cohort 
(N=1694) 
P value 
Male sex 44.9% (340/758) 58.9% (997/1694) 0.0001 
Age; years ± SD 53.9 ± 12.4 51 ± 13.3 0.0001 
BMI ± SD 36.4 ± 10.1 31.7 ± 6.9 0.0001 
Obesity (BMI>30) 64.9% (491/757) 52.3% (882/1688) 0.0001 
Arterial Hypertension 43.4% (326/752) 47.3% (679/1436) 0.080 
Type 2 Diabetes Mellitus 27.6% (209/758) 37.8% (634/1679) 0.0001 
Glucose ± SD (mg/dL) 110 ± 36 113 ± 43 0.047 
HOMA-IR ± SD 4.7 ± 4.3 6.3 ± 10 0.0001 
Total cholesterol ± SD (mg/dL) 195 ± 44 194 ± 48 0.731 
HDL-c ± SD (mg/dL) 53 ± 22 45 ± 19 0.0001 
Triglycerides ± SD (mg/dL) 155 ± 81 166 ± 104 0.004 
Albumin ± SD (g/dL) 4.38 ± 0.4 4.40 ± 0.4 0.292 
Bilirubin ± SD (mg/dL) 0.75 ± 1.01 0.69 ± 0.42 0.033 
Creatinine ± SD (mg/dL) 0.83 ± 0.3 0.85 ± 0.3 0.126 
Platelet count ± SD (x 109/L) 251 ± 73 230 ± 66 0.0001 
AST ± SD (IU/mL) 35 ± 26 46 ± 32 0.0001 
ALT ± SD (IU/mL) 50 ± 40 66 ± 52 0.0001 
NASH 47.2% (358/758) 43% (726/1688) 0.052 
Significant fibrosis (F2-F4) 22% (167/758) 44.7% (758/1694) 0.0001 
Advanced fibrosis (F3-F4) 12.1% (92/758) 24.4% (414/1694) 0.0001 
Cirrhosis 2.9% (22/758) 7% (118/1694) 0.0001 
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Characteristic Unadjusted (Univariable Analysis) Adjusted (Multivariable Analysis) 
Female sex OR 2.14 (95%CI 1.33-3.42); p=0.002 OR 2.40 (95%CI 1.33-4.33); p=0.004 
Age 
< 45 years old 
45-64 years old 
> 65 years old 
 
Reference 
OR 3.80 (95%CI 1.60-9.05); p=0.003 
OR 10.01 (95%CI 4.09-24.51); p=0.0001 
 
Reference 
OR 2.68 (95%CI 1.06-6.77); p=0.037 
OR 5.58 (95%CI 2.09-14.92); p=0.001 
HOMA – DM 
HOMA < 2 
HOMA 2 – 3.99 
HOMA > 4 
Diabetes mellitus 
 
Reference 
OR 1.69 (95%CI 0.58-4.91); p=0.333 
OR 4.74 (95%CI 1.77-12.71); p=0.002 
OR 9.18 (95%CI 3.56-23.66); p=0.0001 
 
Reference 
OR 2.46 (CI95% 0.76-7.92); p=0.132 
OR 4.47 (95%CI 1.49-13.42); p=0.008 
OR 8.88 (95%CI 3.10-25.44); p=0.0001 
Albumin 
> 4.5 g/dL 
4 – 4.49 g/dL 
< 4 g/dL 
 
Reference 
OR 1.86 (95%CI 1.11-3.12); p=0.018 
OR 3.81 (95%CI 2.01-7.25); p=0.0001 
 
Reference 
OR 1.03 (95%CI 0.56-1.88); p=0.929 
OR 2.45 (95%CI 1.14-5.29); p=0.022 
Platelet count 
> 220 x 109/L 
155 – 219 x 109/L 
< 155 x 109/L 
 
Reference 
OR 2.25 (95%CI 1.35-3.74); p=0.002 
OR 12.50 (95%CI 6.54-23.89); p=0.0001 
 
Reference 
OR 2.42 (95%CI 1.35-4.34); p=0.003 
OR 9.33 (95%CI 4.01-21.67); p=0.0001 
AST 
< 35 IU/mL 
35 – 69 IU/mL 
> 70 IU/mL 
 
Reference 
OR 2.94 (95%CI 1.79-4.83); p=0.0001 
OR 9.42 (95%CI 4.89-18.13); p=0.0001 
 
Reference 
OR 2.45 (95%CI 1.37-4.38); p=0.002 
OR 8.38 (95%CI 3.72-18.91); p=0.0001 
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Estimation Cohort (n=758) 
 Hepamet Fibrosis Score NAFLD Fibrosis Score FIB-4 
Advanced Fibrosis (F0-2 vs. F3-4) 0.850 (95%CI 0.807-0.893) 0.775 (95%CI 0.723-0.828) 
p=0.0025 
0.772 (95%CI 0.713-0.832) 
p=0.0002 
 
Validation Cohort (n=1694) 
 Hepamet Fibrosis Score NAFLD Fibrosis Score FIB-4 
Advanced Fibrosis (F0-2 vs. F3-4) 0.844 (95%CI 0.819-0.869) 0.789 (95%CI 0.764-0.814) 
p<0.0001 
0.801 (95%CI 0.776-0.826) 
p<0.0001 
 
Overall Cohort (N=2452) 
 Hepamet Fibrosis Score NAFLD Fibrosis Score FIB-4 
Advanced Fibrosis (F0-2 vs. F3-4) 0.848 (95%CI 0.826-0.869) 0.778 (95%CI 0.756-0.801) 
p<0.0001 
0.802 (95%CI 0.780-0.825) 
p<0.0001 
 
p value vs. Hepamet Fibrosis Score 
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 Estimation Cohort Validation Cohort 
Advanced Fibrosis (%) 12.1% 24.6% 
Cut-off < 0.12 ≥ 0.47 < 0.12 ≥ 0.47 
Sensitivity (%) 70.7 38 74.6 34.6 
Specificity (%) 80.9 98 75.5 96.7 
PPV (%) 33.9 72.9 49.8 77.2 
NPV (%) 95.2 92 90.1 81.9 
LR+ 3.71 15.24 3.05 10.40 
LR- 0.36 0.63 0.34 0.68 
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Characteristic Spanish 
Cohort (n=758) 
French cohort 
No. 1 (N=444) 
French cohort 
No. 2 (N=386) 
Cuban Cohort 
(n=344) 
Italian Cohort 
(n=288) 
Chinese 
Cohort (n=232) 
Male sex 44.9% 60.4% 61.1% 42.2% 62.5% 72.4% 
Age; years ± SD 53.9 ± 12.4 54.2 ± 12.3 56.1 ± 12.2 51.1 ± 12.8 46.2 ± 13.3 42.5 ± 12.4 
BMI ± SD 36.4 ± 10.1 31.4 ± 6.5 32.5 ± 6 36 ± 8.3 29.9 ± 5.1 26.7 ± 4.3 
Obesity (BMI>30) 64.9% 50.7% 63.5% 74.7% 44% 13.4% 
Arterial Hypertension 43.4% 48.1% 57.5% 50.9% 28.1% 27% 
Type 2 Diabetes Mellitus 27.6% 45.9% 43.8% 43.9% 21.5% 24.1% 
Glucose ± SD (mg/dL) 110 ± 36 116 ± 43 122 ± 47 118 ± 48 99 ± 31 103 ± 30 
HOMA-IR ± SD 4.7 ± 4.3 4.8 ± 5 8.5 ± 14 7.9 ± 12.9 4.1 ± 3 5.9 ± 8 
Total cholesterol ± SD (mg/dL) 195 ± 44 190 ± 46 197 ± 47 189 ± 52 206 ± 46 194 ± 46 
HDL-c ± SD (mg/dL) 53 ± 22 45 ± 17 45 ± 14 44 ± 32 51 ± 17 40 ± 9 
Triglycerides ± SD (mg/dL) 155 ± 81 150 ± 93 167 ± 113 174 ± 97 146 ± 78 210 ± 131 
Albumin ± SD (g/dL) 4.38 ± 0.4 4.38 ± 0.4 4.25 ± 0.4 4.26 ± 0.5 4.60 ± 0.4 4.64 ± 0.3 
Bilirubin ± SD (mg/dL) 0.75 ± 1.01 0.63 ± 0.47 0.68 ± 0.42 0.69 ± 0.40 0.67 ± 0.35 0.82 ± 0.38 
Creatinine ± SD (mg/dL) 0.83 ± 0.3 0.90 ± 0.25 0.83 ± 0.18 0.90 ± 0.35 0.88 ± 0.34 0.76 ± 0.17 
Platelet count ± SD (x 109/L) 251 ± 73 229 ± 63 223 ± 67 223 ± 69 232 ± 69 250 ± 58 
AST ± SD (IU/mL) 35 ± 26 46 ± 30 46 ± 34 44 ± 21 46 ± 21 46 ± 32 
ALT ± SD (IU/mL) 50 ± 40 60 ± 42 63 ± 38 61 ± 53 81 ± 51 73 ± 74 
NASH 47.2% 46.5% 29.9% 31.7% 80.9% 28% 
Significant fibrosis (F2-F4) 22% 52.3% 61.9% 35.8% 46.9% 12.5% 
Advanced fibrosis (F3-F4) 12.1% 27.3% 35.8% 25.3% 20.8% 3.4% 
Cirrhosis 2.9% 6.8% 7.3% 11.3% 7.3% 0% 
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Characteristic Fibrosis F3-4 
(n=92) 
Fibrosis F0-2 
(N=666) 
Univariable 
Analysis 
Multivariable 
Analysis 
Female sex 70.7% (65/92) 53% (353/666) 0.001 OR 2.08 (95%CI 
1.18-3.66); 
p=0.011 
Age; years ± SD 61.1 ± 10.1 52.9 ± 12.3 0.0001 OR 1.05 (95%CI 
1.03-1.08); 
p=0.0001 
BMI ± SD 37.5 ± 10.2 36.2 ± 10.1 0.247  
Obesity (BMI>30) 70.7% (65/92) 64.1% (426/665) 0.214  
Arterial Hypertension 64.4% (58/90) 40.5% (268/662) 0.0001  
Type 2 Diabetes Mellitus 54.3% (50/92) 23.9% (159/666) 0.0001 OR 1.66 (95%CI 
0.92-3.00); 
p=0.093 
Glucose ± SD (mg/dL) 129 ± 50 107 ± 33 0.0001  
HOMA-IR ± SD 8.6 ± 7 4.2 ± 3.4 0.0001 OR 1.16 (95%CI 
1.10-1.23); 
p=0.0001 
Total cholesterol ± SD (mg/dL) 185 ± 43 197 ± 44 0.017  
HDL-c ± SD (mg/dL) 50 ± 23 53 ± 22 0.244  
Triglycerides ± SD (mg/dL) 161 ± 69 154 ± 83 0.480  
Albumin ± SD (g/dL) 4.20 ± 0.45 4.40 ± 0.4 0.0001 OR 2.54 (95%CI 
1.30-4.98); 
p=0.006 
Bilirubin ± SD (mg/dL) 1.05 ± 2.55 0.71 ± 0.52 0.216  
Creatinine ± SD (mg/dL) 0.85 ± 0.4 0.83 ± 0.3 0.571  
Platelet count ± SD (x 109/L) 209 ± 85 257 ± 70 0.0001 OR 0.99 (95%CI 
0.987-0.995); 
p=0.0001 
AST ± SD (IU/mL) 50 ± 31 32 ± 25 0.0001 OR 1.02 (95%CI 
1.01-1.03); 
p=0.0001 
ALT ± SD (IU/mL) 62 ± 41 48 ± 40 0.002  
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Spanish Cohort (n=758) 
 Hepamet Fibrosis Score NAFLD Fibrosis Score FIB-4 
Advanced Fibrosis (F0-
2 vs. F3-4) 
0.850 (95%CI 0.807-0.893) 0.775 (95%CI 0.723-0.828) 0.772 (95%CI 0.713-0.832) 
 
French Cohort No. 1 (n=444) 
 Hepamet Fibrosis Score NAFLD Fibrosis Score FIB-4 
Advanced Fibrosis (F0-
2 vs. F3-4) 
0.800 (95%CI 0.751-0.849) 0.768 (95%CI 0.717-0.820) 0.764 (95%CI 0.710-0.817) 
 
French Cohort No. 2 (n=386) 
 Hepamet Fibrosis Score NAFLD Fibrosis Score FIB-4 
Advanced Fibrosis (F0-
2 vs. F3-4) 
0.810 (95%CI 0.766-0.853) 0.749 (95%CI 0.700-0.799) 0.765 (95%CI 0.716-0.815) 
 
Italian Cohort (n=288) 
 Hepamet Fibrosis Score NAFLD Fibrosis Score FIB-4 
Advanced Fibrosis (F0-
2 vs. F3-4) 
0.843 (95%CI 0.790-0.895) 0.785 (95%CI 0.711-0.858) 0.773 (95%CI 0.706-0.840) 
 
Cuban Cohort (n=344) 
 Hepamet Fibrosis Score NAFLD Fibrosis Score FIB-4 
Advanced Fibrosis (F0-
2 vs. F3-4) 
0.854 (95%CI 0.810-0.899) 0.768 (95%CI 0.709-0.828) 0.830 (95%CI 0.781-0.880) 
 
Chinese Cohort (n=232) 
 Hepamet Fibrosis Score NAFLD Fibrosis Score FIB-4 
Advanced Fibrosis (F0-
2 vs. F3-4) 
0.904 (95%CI 0.829-0.979) 0.812 (95%CI 0.709-0.915) 0.787 (95%CI 0.644-0.930) 
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ADVANCED FIBROSIS (prevalence 20.6%) 
 Hepamet Fibrosis Score NAFLD Fibrosis Score FIB-4 
Cut-off < 0.12 ≥ 0.47 < -1.455 > 0.675 < 1.30 ≥ 2.67 
Sensitivity (%) 73.9 35.2 70.5 32.9 66.9 29.6 
Specificity (%) 77.4 97.2 63.6 93.2 74.8 97.3 
PPV (%) 46 76.3 33.5 55.6 40.8 74.1 
NPV (%) 91.9 85.2 89.3 84.2 89.7 84.2 
LR+ 3.27 13.22 1.94 4.81 2.66 10.03 
LR- 0.31 0.67 0.46 0.72 0.44 0.72 
Post-Test Probability (+) 
(%) 
46 79.7 33.5 55.5 40.8 74.1 
Post-Test Probability (-) 
(%) 
6.4 13.5 10.7 15.7 10.3 15.8 
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 HFS vs. FIB-4 HFS vs. NFS 
 Values P-Value Values P-Value 
NRI (95% CI) 25.3% (16-33.7) <0.0001 31.7% (15.1-48.2) <0.0001 
% of events correctly reclassified 2.2% <0.0001 4.4% <0.0001 
% of non-events correctly reclassified 23.1% <0.0001 27.3% <0.0001 
IDI (95% CI) 0.0700  
(0.0624-0.0776) 
<0.0001 0.1170  
(0.1077-0.1263) 
<0.0001 
 
 
